{"id":"NCT00531427","sponsor":"Purdue Pharma LP","briefTitle":"Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee","officialTitle":"Randomized, Double-blind, Placebo-controlled With Open-label Run-in Assessing Efficacy, Tolerability,Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects w/Moderate to Severe, Chronic Pain Due to OA of Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-04","completion":"2009-11","firstPosted":"2007-09-18","resultsPosted":"2010-09-21","lastUpdate":"2012-09-10"},"enrollment":567,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain","Osteoarthritis of the Knee"],"interventions":[{"type":"DRUG","name":"Buprenorphine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. The double-blind treatment intervention duration is 12 weeks, during which time supplemental analgesic medication (immediate-release oxycodone for the first 6 days postrandomization and acetaminophen or ibuprofen for the remainder of the double-blind phase) will be provided to all subjects in addition to study drug.","primaryOutcome":{"measure":"\"Average Pain Over the Last 24 Hours\" Score of the Study Knee at Week 12 of the Double Blind Phase.","timeFrame":"24 hours (week 12)","effectByArm":[{"arm":"Double-blind BTDS 10 or 20","deltaMin":7.16,"sd":1.34},{"arm":"Double-blind Placebo","deltaMin":7.06,"sd":1.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0853"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":87,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":282},"commonTop":["Nausea","Application site pruritus","Dizziness","Somnolence","Headache"]}}